Thursday, May 23, 2013

Antares Pharma, Inc. (ATRS) Adds Marvin Samson to Board of Directors


Antares Pharma is focused on self-administered parenteral pharmaceutical products and topical gel-based medicines. The company is developing products in conjunction with various partners that will help people deal with rheumatoid arthritis, psoriasis, overactive bladder, menopause, and other medical problems.

The company reported today that Marvin Samson has been elected to its Board of Directors by shareholders at the annual shareholder meeting. He is an expert in injectable manufacturing and delivery systems, which is a big part of Antares Pharma’s business. Samson was formerly the group vice-president – worldwide of Teva Pharmaceutical Industries. He has served as CEO and member of the Board at Sicor and was also a founder and CEO of Elkins-Sinn and Marsam Pharmaceuticals.

Additionally, Samson is the founder and CEO of Samson Medical Technologies, a privately-held company providing hospital and alternative site pharmacists with injectable drug delivery systems and programs. He is also Chairman of the Board of JHP Pharmaceuticals and serves on the Board of Directors of Flynn Pharma, NanoPass Technologies, and Emcure Pharmaceuticals. In the past, he served as Chairman of Endo Pharmaceuticals. Samson also holds five patents pertaining to pharmaceutical manufacturing.

Antares’ management is enthused to have Mr. Samson aboard. The company’s CEO, Paul K. Wotton, Ph.D., said, “His extensive commercial expertise in injectable manufacturing and delivery systems will be invaluable as we launch new products and add to an already exciting pipeline. The company’s chairman, Leonard S. Jacob, M.D., Ph.D., added “His broad expertise in all aspects of our business will be an important asset to us as we prepare to launch OTREXUP early next year.” OTREXUP is a combination product for the delivery of methotrexate using its Medi-Jet technology for the treatment of rheumatoid arthritis.

For further information about Antares Pharma, its technologies, and product pipeline, please visit www.antarespharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html